Daré Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting
Data to be presented demonstrate increased frequency of sexual events with Sildenafil Cream, 3.6% use in the Phase 2b RESPOND clinical study, as well as improvement in multiple aspects of
the sexual experience
Continuing to work toward Phase 3 pivotal study
There are no FDA-approved treatments for female sexual arousal disorder
SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that additional data from the exploratory Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6% (Sildenafil Cream) in women with female sexual arousal disorder (FSAD) will be presented at the upcoming International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting. These data include efficacy results across multiple endpoints in the proposed Phase 3 study population.
Presentation Details
Poster 1: |
Sexual Experiences in an Exploratory, Phase 2b, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Sildenafil, 3.6% Cream for the Treatment of Female Sexual Arousal
Disorder https://www1.statusplus.net/misc/posters/isswsh/annual2024/search/post ... |
Poster 2: |
Impact of Enrollment Diagnosis on Efficacy Endpoints in an Exploratory, Phase 2b, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Sildenafil Cream, 3.6% for the Treatment of
Female Sexual Arousal Disorder https://www1.statusplus.net/misc/posters/isswsh/annual2024/search/post ... |
Poster 3: |
Female Sexual Distress in an Exploratory, Phase 2b, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Sildenafil Cream, 3.6% for the Treatment of Female Sexual Arousal
Disorder https://www1.statusplus.net/misc/posters/isswsh/annual2024/search/post ... |
Session: | Poster Session 8 - Novel Drugs, Methods and Technologies (non-CME) |
Presenter: | Andrew T. Goldstein, MD |
Date / Time: | Saturday, February 24, 2024; 10:05 a.m. – 10:35 a.m. PST |
Location: | Long Beach, CA |
Lesen Sie auch
“The data from the Phase 2b RESPOND study demonstrate that Sildenafil Cream treatment reduced sexual distress across multiple measures in a clinically meaningful way,” said Dr. Andrew Goldstein, Medical Advisor for Daré Bioscience and former President of ISSWSH. “The results highlight specific endpoints with the strongest responses including arousal sensation, desire, orgasm, as well as stress, guilt, and embarrassment about the sexual dysfunction. Most importantly, based on these responses, we’ve identified the study population that will likely demonstrate the most significant benefit from Sildenafil Cream treatment, which consists of healthy premenopausal women with female sexual arousal disorder, including those who suffered from a lack of sexual desire due to their decreased arousal.”